December 15, 2024European Journal of Heart Failure16 citationsOpen Access
View Full PaperEmpagliflozin to Prevent Worsening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction (EMPRESS-MI)
Structured PICO
Does empagliflozin improve cardiac volumes or LVEF in patients with left ventricular systolic dysfunction after an acute MI?
P
Population
patients with left ventricular systolic dysfunction after an acute MI receiving contemporary standard of care
I
Intervention
empagliflozin
C
Comparator
placebo
O
Outcome
cardiac volumes or LVEFsurrogate
Empagliflozin does not prevent adverse cardiac remodeling or improve LVEF in patients with LV systolic dysfunction post-MI on standard of care.
Abstract
In patients with left ventricular systolic dysfunction after an acute MI receiving contemporary standard of care, treatment with empagliflozin had no effect on cardiac volumes or LVEF compared with placebo. Progressive adverse cardiac remodelling did not occur in the majority of patients.